Lifestyle management in polycystic ovary syndrome - beyond diet and physical activity.

Women with PCOS have an increased risk of both clinical sleep disorders and non-clinical sleep disturbance, which is mediated by hormone derangement, in particular reduced oestrogen, progesterone and melatonin levels [ 164 ]. Oestrogen is required for the metabolism of neurotransmitters (norepinephrine and serotonin) involved in regulating sleep patterns, and plays an important role in maintaining a low body temperature at night [ 165 ]. Progesterone has sedative and anxiolytic actions that can support sleep quality, and acts as a respiratory stimulant that lessens airway resistance in obstructive sleep apnoea (OSA) [ 166 ]. Melatonin is a neuroendocrine hormone that is widely recognised as crucial in maintaining circadian rhythm regulation. However, melatonin is also involved in ovarian function, with actions including delaying ovarian senescence, promoting follicle formation and improving oocyte quality [ 167 – 173 ]. The current PCOS guideline recognises that OSA is 6.5-8.3 times more likely in women with PCOS [ 164 , 174 – 177 ], and promotes routine screening to identify and treat associated symptoms, such as snoring, excessive sleepiness and the potential for fatigue to worsen mood disorders [ 18 ]. Screening should include a simple questionnaire, such as the Berlin tool [ 178 ], and where appropriate women should be referred onto a specialist for further assessment and treatment [ 18 ]. The guidelines also highlight that treatment of OSA in PCOS should not be used to improve metabolic features. Since guideline inception evidence has emerged reporting weight, PCOS and sleep are interrelated factors that can each contribute to the worsening presentation of one another, whereby sleep disorders and disturbance may worsen the presentation of PCOS related metabolic outcomes and vice versa [ 179 ]. Hypersomnia and insomnia are also common clinical sleep disorders in PCOS [ 164 , 177 , 180 ], with prevalence estimated at 11% versus 1% in women with versus those without PCOS [ 180 ]. Even in the absence of clinically diagnosed sleep disorders, women with PCOS have a higher prevalence of sleep disturbances, including poor sleep quality [ 181 ], issues with sleep initiation [ 182 ], severe fatigue [ 140 ], restless sleep [ 140 ] and difficulty sleeping overnight [ 140 ]. The prevalence of sleep disturbances may be up to 20% higher in women with PCOS compared to women without PCOS [ 183 ]. Emerging research also suggests that social restrictions arising from the COVID-19 pandemic have worsened sleep disturbances in women with PCOS [ 177 ]. Findings from key studies of non-clinical sleep disturbance can be found in Table 4 . Table 4 Key observational studies that report non-clinical sleep disruption in polycystic ovary syndrome Reference Sample size Sleep methodology used Main findings Moran et al. 2015 [ 182 ] PCOS: n =87 Non-PCOS: n =637 Modified version of the Jenkins Sleep Questionnaire Women with PCOS were twice as likely to experience sleep disturbance PCOS was associated with difficulty falling asleep and maintaining sleep Mo et al 2019 [ 140 ] a PCOS: n =484 Non-PCOS: n =6094 Sleep duration was self-reported on a work day and non-work day Sleep quality was self-reported through frequency questions about difficulty falling asleep, restless sleep, difficulty sleeping and severe tiredness Women with/without PCOS had similar sleep duration Women with PCOS had higher prevalence of sleep disturbance, and this relationship maintained even after controlling for BMI, depression, income, marital status, occupation, education status and COB Bennett et al. 2021 [ 183 ] a PCOS: n =464 Non-PCOS: n =5603 Sleep duration was self-reported on a work day and non-work day Sleep quality was self-reported through frequency questions about difficulty falling asleep, restless sleep, difficulty sleeping and severe tiredness Overall women with PCOS had greater adverse sleep symptoms and higher DGI However, subgroup analysis revealed PCOS was only associated with a higher DGI in women with adequate sleep There was no association between PCOS and DGI in women with poor sleep The higher DGI observed in women with PCOS may only be maintained in women who achieve adequate amounts of good quality sleep Shreeve et al. 2013 [ 167 ] PCOS: n =15 Non-PCOS: n =18 Actigraphy, PSQI and ESS Women with PCOS had higher night time melatonin levels Women with PCOS had reduced sleep when compared to controls Kutanaee et al. 2019 [ 181 ] PCOS: n =201 Non-PCOS: n =199 PSQI Women with PCOS had lower sleep quality and daytime function Women with PCOS were more likely to utilise medication to assist with sleep Abbreviations : BMI Body mass index, COB Country of birth, DGI Dietary Guidelines Index, ESS Epworth Sleepiness Scale, PCOS Polycystic ovary syndrome, PQSI Pittsburgh Sleep Quality Index a Mo et al. [ 140 ] and Bennett et al. [ 183 ] share the same cohort Key observational studies that report non-clinical sleep disruption in polycystic ovary syndrome PCOS: n =87 Non-PCOS: n =637 Women with PCOS were twice as likely to experience sleep disturbance PCOS was associated with difficulty falling asleep and maintaining sleep PCOS: n =484 Non-PCOS: n =6094 Sleep duration was self-reported on a work day and non-work day Sleep quality was self-reported through frequency questions about difficulty falling asleep, restless sleep, difficulty sleeping and severe tiredness Women with/without PCOS had similar sleep duration Women with PCOS had higher prevalence of sleep disturbance, and this relationship maintained even after controlling for BMI, depression, income, marital status, occupation, education status and COB PCOS: n =464 Non-PCOS: n =5603 Sleep duration was self-reported on a work day and non-work day Sleep quality was self-reported through frequency questions about difficulty falling asleep, restless sleep, difficulty sleeping and severe tiredness Overall women with PCOS had greater adverse sleep symptoms and higher DGI However, subgroup analysis revealed PCOS was only associated with a higher DGI in women with adequate sleep There was no association between PCOS and DGI in women with poor sleep The higher DGI observed in women with PCOS may only be maintained in women who achieve adequate amounts of good quality sleep PCOS: n =15 Non-PCOS: n =18 Women with PCOS had higher night time melatonin levels Women with PCOS had reduced sleep when compared to controls PCOS: n =201 Non-PCOS: n =199 Women with PCOS had lower sleep quality and daytime function Women with PCOS were more likely to utilise medication to assist with sleep Abbreviations : BMI Body mass index, COB Country of birth, DGI Dietary Guidelines Index, ESS Epworth Sleepiness Scale, PCOS Polycystic ovary syndrome, PQSI Pittsburgh Sleep Quality Index a Mo et al. [ 140 ] and Bennett et al. [ 183 ] share the same cohort In the general population short and disturbed sleep is consistently associated with excess weight [ 184 ], IR [ 185 ], T2DM [ 185 ] and CVD [ 186 ]. Similar relationships are observed in PCOS, where OSA and sleep disordered breathing exacerbates risk of IR and metabolic consequences of abnormal glucose tolerance [ 187 , 188 ]. A cross-sectional study in adolescents with PCOS ( n =103) reported those with sleep disordered breathing had significantly higher BMI Z-scores, and a higher prevalence of metabolic syndrome (METS) [ 188 ]. Similar metabolic consequences are seen in women with PCOS who suffer from non-clinical sleep disturbance [ 164 ]. Underlying mechanisms linking sleep disorders and disturbance with worsened metabolic outcomes include amplified sympathetic tone and oxidative stress [ 164 ], reduced adipose tissue lipolysis, and an increase in energy intake stemming from heightened hedonic and endocrine appetite signals [ 189 ]. Unfavourable effects on energy metabolism and appetite regulation, may explain why women with PCOS who display sleep disturbance have a reduced capacity to maintain dietary interventions [ 183 ]. Moreover, depression and anxiety share a bidirectional relationship with disrupted and reduced sleep [ 190 ], and as stated previously, interventions that improve mental health can help to increase engagement with dietary and physical activity recommendations [ 131 ]. Optimising sleep may therefore be an important consideration when promoting healthy lifestyle change in women with PCOS [ 183 ].

The 2018 International Evidence-Based Guideline for the Assessment and Management of PCOS highlights lifestyle (diet, physical activity and/or behavioural) management as the primary initial treatment strategy [ 18 ]. It is important to consider that the definition of lifestyle management may warrant expansion consistent with the whole person model of healthcare provision, which may include care addressing psychological and sleep interventions, as well as a range of TCIM approaches [ 20 ]. In line with patient interest [ 31 – 35 ], and to assist women and healthcare providers in understanding the evidence to aid safe implementation of adjunct therapies, rigorous assessment of the evidence for these alternative lifestyle strategies in PCOS management in warranted. Using a holistic definition of patient care, this review has summarised evidence to date on the traditional components of lifestyle change (diet, physical activity and behavioural change), psychological interventions and non-pharmacological strategies (sleep, supplements, herbal medicine and other TCIM approaches). Table 6 provides a overview of current guideline recommendations alongside the key findings from this review, summarising the identified research gaps that need to be addressed before evidence-based recommendations for clinical practice can be updated. Table 6 Current recommendations for clinical practice and research gaps identified by this review Recommendation(s) from current guidelines a Category of recommendation b Research gaps Effectiveness of lifestyle interventions  Healthy lifestyle behaviours encompassing healthy eating and regular physical activity should be recommended in all those with PCOS to achieve and/or maintain healthy weight and to optimise hormonal outcomes, general health, and QoL across the life course. CCR • Improves sustainability of weight loss interventions. • Identifies subgroups who respond to weight loss with clinically relevant metabolic and reproductive improvements (this requires the inclusion of more clinical reproductive outcomes in RCTs). • Defines weight loss thresholds for improvements in different PCOS features (metabolic, reproductive and psychological). • Characterises the degree of metabolic and reproductive improvements related to different lifestyle factors (diet, physical activity and behavioural) independent of weight changes. • Considers effects of weight gain prevention on limiting the progression/worsening of PCOS features. • Investigates how different dietary, physical activity and behavioural interventions affect engagement, adherence and sustainability of lifestyle change. • Investigates efficacy and effectiveness of healthy lifestyle changes independent of weight change.  Lifestyle intervention (preferably multicomponent including diet, exercise and behavioural strategies) should be recommended in all those with PCOS and excess weight, for reductions in weight, central obesity and IR. EBR  Achievable goals such as 5% to 10% weight loss in those with excess weight yields significant clinical improvements and is considered successful weight reduction within six months. Ongoing assessment and monitoring is important during weight loss and maintenance in all women with PCOS. CPP  SMART (Specific Measurable, Achievable, Realistic and Timely) goal setting and self-monitoring can enable achievement of realistic lifestyle goals. CPP  Psychological factors such as anxiety and depressive symptoms, body image concerns and disordered eating, need consideration and management to optimise engagement and adherence to lifestyle interventions. CPP  Health professional interactions around healthy lifestyle, including diet and exercise, need to be respectful, patient-centred and to value women’s individualised healthy lifestyle preferences and cultural, socioeconomic and ethnic differences. Health professionals need to also consider personal sensitivities, marginalisation and potential weight-related stigma. CPP  Healthy lifestyle may contribute to health and QoL benefits in the absence of weight loss. CPP  Healthy lifestyle and optimal weight management appears equally effective in PCOS as in the general population and is the joint responsibility of all health professionals, partnering with women with PCOS. Where complex issues arise, referral to suitably trained allied health professionals needs to be considered. CPP Dietary interventions  A variety of balanced dietary approaches could be recommended to reduce dietary energy intake and induce weight loss in women with PCOS and overweight and obesity, as per general population recommendations. CCR • Low GI/GL diets may provide benefits in reducing weight and IR in women with PCOS. Further research needs to assess additional risk factors including reproductive function and CVD risk. • Identify and define the optimal diet for PCOS management by comparing a range of different dietary approaches (e.g. DASH, Mediterranean or low GI/GL).  General healthy eating principles should be followed for all women with PCOS across the life course, as per general population recommendations. CCR  To achieve weight loss in those with excess weight, an energy deficit of 30% or 500 - 750 kcal/day (1,200 to 1,500 kcal/day) could be prescribed for women, also considering individual energy requirements, body weight and physical activity levels. CPP  In women with PCOS, there is no or limited evidence that any specific energy equivalent diet type is better than another, or that there is any differential response to weight management intervention, compared to women without PCOS. CPP  Tailoring of dietary changes to food preferences, allowing for a flexible and individual approach to reducing energy intake and avoiding unduly restrictive and nutritionally unbalanced diets, are important, as per general population recommendations. CPP Physical activity interventions  Health professionals should encourage and advise the following for prevention of weight gain and maintenance of health: • in adults from 18 – 64 years, a minimum of 150 min/week of moderate intensity physical activity or 75 min/week of vigorous intensities or an equivalent combination of both, including muscle strengthening activities on 2 non-consecutive days/week; • in adolescents, at least 60 minutes of moderate to vigorous intensity physical activity/day, including those that strengthen muscle and bone at least 3 times weekly; • activity be performed in at least 10-minute bouts or around 1000 steps, aiming to achieve at least 30 minutes daily on most days. CCR While evidence supports the provision of supervised vigorous aerobic exercise, which may provide greater benefits on PCOS symptoms than other types of exercise (e.g. resistance training), additional larger and longer-term studies are required to: • Characterise optimal exercise prescription for PCOS management. • Identify factors that improve adherence to exercise interventions. • Identify subgroups who respond to exercise with clinical improvements.  Health professionals should encourage and advise the following for modest weight-loss, prevention of weight-regain and greater health benefits: • a minimum of 250 min/week of moderate intensity activities or 150 min/week of vigorous intensity or an equivalent combination of both, and muscle strengthening activities involving major muscle groups on 2 non-consecutive days/week; • minimised sedentary, screen or sitting time. CCR  Physical activity includes leisure time physical activity, transportation such as walking or cycling, occupational work, household chores, games, sports or planned exercise, in the context of daily, family and community activities. Daily, 10000 steps is ideal, including activities of daily living and 30 minutes of structured physical activity or around 3000 steps. Structuring of recommended activities need to consider women’s and family routines as well as cultural preferences. CPP Behavioural interventions  Lifestyle interventions could include behavioural strategies such as goal-setting, self-monitoring, stimulus control, problem solving, assertiveness training, slower eating, reinforcing changes and relapse prevention, to optimise weight management, healthy lifestyle and emotional wellbeing in women with PCOS. CCR • To identify behavioural and cognitive strategies that should be targeted in women with PCOS, more observational research that characterises women’s use of self-management strategies is needed. • To aid replication and interpretation of findings, RCTs must clearly define the theoretical frameworks and behavioural components used in intervention design.  Comprehensive health behavioural or cognitive behavioural interventions could be considered to increase support, engagement, retention, adherence and maintenance of healthy lifestyle and improve health outcomes in women with PCOS. CPP Assessment and treatment of infertility (as it relates to alcohol and smoking use) Cardiovascular disease risk (as it relates to alcohol and smoking use)  Factors such as blood glucose, weight, blood pressure, smoking, alcohol, diet, exercise, sleep and mental, emotional and sexual health need to be optimised in women with PCOS, to improve reproductive and obstetric outcomes, aligned with recommendations in the general population. CPP • Determine whether women with PCOS are at a higher risk of alcohol and smoking-related infertility complications (with a focus on anovulatory infertility) when compared to women without PCOS. • Determine whether women with PCOS are at a higher risk of smoking-related CVD complications when compared to women without PCOS.  If screening reveals CVD risk factors including obesity, cigarette smoking, dyslipidemia, hypertension, impaired glucose tolerance and lack of physical activity, women with PCOS should be considered at increased risk of CVD. CCR Quality of life  Health professionals and women should be aware of the adverse impact of PCOS on quality of life. CCR • Validate QoL tools longitudinally to identify clinically meaningful differences in QoL scores.  Health professionals should capture and consider perceptions of symptoms, impact on quality of life and personal priorities for care to improve patient outcomes. CCR  The PCOS quality of life tool (PCOSQ), or the modified PCOSQ, may be useful clinically to highlight PCOS features causing greatest distress, and to evaluate treatment outcomes on women’s subjective PCOS health concerns. CPP Depression and anxiety symptoms, screening and treatment Psychosexual function Body image Eating disorders and disordered eating  Health professionals should be aware that in PCOS, there is a high prevalence of moderate to severe anxiety and depressive symptoms in adults; and a likely increased prevalence in adolescents. CCR • To determine accurate prevalence of psychological conditions in PCOS, more adequately powdered cross-sectional studies using structured diagnostic interviews administered by appropriately qualified professionals are required. • Future research should consider the efficacy of different types of psychological interventions in PCOS, with a focus on how changes to mental health symptoms influence engagement with lifestyle change. In particular, the development of a PCOS specific CBT program, tailored to meet the specific mental health needs of women with PCOS is warrant.  Anxiety and depressive symptoms should be routinely screened in all adolescents and women with PCOS at diagnosis. If the screen for these symptoms and/or other aspects of emotional wellbeing is positive, further assessment and/or referral for assessment and treatment should be completed by suitably qualified health professionals, informed by regional guidelines. CCR  If treatment is warranted, psychological therapy and/or pharmacological treatment should be offered in PCOS, informed by regional clinical practice guidelines. CCR  Factors including obesity, infertility, hirsutism need consideration along with use of hormonal medications in PCOS, as they may independently exacerbate depressive and anxiety symptoms and other aspects of emotional wellbeing. CPP  All health professionals should be aware of the increased prevalence of psychosexual dysfunction and should consider exploring how features of PCOS, including hirsutism and body image, impact on sex life and relationships in PCOS. CCR  If psychosexual dysfunction is suspected, tools such as the Female Sexual Function Index can be considered. CCR  Health professionals and women should be aware that features of PCOS can impact on body image. CCR  All health professionals and women should be aware of the increased prevalence of eating disorders and disordered eating associated with PCOS. CCR  If eating disorders and disordered eating are suspected, further assessment, referral and treatment, including psychological therapy, could be offered by appropriately trained health professionals, informed by regional clinical practice guidelines. CCR Obstructive sleep apnoea (OSA)  Screening should only be considered for OSA in PCOS to identify and alleviate related symptoms, such as snoring, waking unrefreshed from sleep, daytime sleepiness, and the potential for fatigue to contribute to mood disorders. Screening should not be considered with the intention of improving cardiometabolic risk, with inadequate evidence for metabolic benefits of OSA treatment in PCOS and in general populations. CCR • To determine accurate prevalence of subclinical sleep disturbances in PCOS, more adequately powdered cross-sectional studies using validated subjective and objective sleep measures are required. • While emerging evidence suggests that disturbed sleep may exacerbate IR via decreasing energy expenditure and increasing adipose tissue deposition, more research in women with PCOS is needed to confirm this hypothesis. • Investigate effects of CBT interventions in women with PCOS who have disturbed sleep (outcomes of interest include food intake, metabolic rate, appetite hormones, weight, adherence to lifestyle changes and PCOS features).  A simple screening questionnaire, preferably the Berlin tool [ 178 ], could be applied and if positive, referral to a specialist considered. CCR  A positive screen raises the likelihood of OSA, however it does not quantify symptom burden and alone does not justify treatment. If women with PCOS have OSA symptoms and a positive screen, consideration can be given to be referral to a specialist centre for further evaluation. CPP Inositol  Inositol (in any form) should currently be considered an experimental therapy in PCOS, with emerging evidence on efficacy highlighting the need for further research. EBR • To reduce heterogeneity across studies investigating supplements or herbal medicine, RCTs should focus on specific populations within PCOS (i.e. age, BMI or phenotype) and adopt more consistent approaches to formulation (i.e. limit co-supplementation), dosage, intervention duration and the type of comparator used. • Mechanistic studies are needed to investigate herb- or nutrient-drug interactions (with common pharmacological treatments used in PCOS) and other possible interactions with the biological processes underpinning PCOS. • Research that characterises the uptake of TCIM approaches by women with PCOS, including where they are sourcing information on this topic, will aid health professionals understanding of how to safely navigate the use of adjunct therapies in PCOS management.  Women taking inositol and other complementary therapies are encouraged to advise their health professional. CPP Abbreviations : BMI Body mass index, CBT Cognitive behavioural therapy, CVD Cardiovascular disease, DASH Dietary approaches to stop hypertension, GI Glycaemic index, GL Glycaemic load, IR Insulin resistance, NAC N-acetyl-cysteine, PCOS Polycystic ovary syndrome, RCT Randomised controlled trial, QoL Quality of life a Recommendations are taken directly from the 2018 International Evidence-Based Guideline for the Assessment and Management of PCOS [ 18 ]. Does not include all recommendations, only those relevant to the findings of this review are presented b EBR Evidence based recommendations: Evidence sufficient to inform a recommendation made by the guideline development group. CCR Clinical Consensus Recommendations: In the absence of evidence, a clinical consensus recommendation has been made by the guideline development group. CPP Clinical Practice Points: Evidence not sought. A practice point has been made by the guideline development group where important issues arose from discussion of evidence-based or clinical consensus recommendations Current recommendations for clinical practice and research gaps identified by this review • Improves sustainability of weight loss interventions. • Identifies subgroups who respond to weight loss with clinically relevant metabolic and reproductive improvements (this requires the inclusion of more clinical reproductive outcomes in RCTs). • Defines weight loss thresholds for improvements in different PCOS features (metabolic, reproductive and psychological). • Characterises the degree of metabolic and reproductive improvements related to different lifestyle factors (diet, physical activity and behavioural) independent of weight changes. • Considers effects of weight gain prevention on limiting the progression/worsening of PCOS features. • Investigates how different dietary, physical activity and behavioural interventions affect engagement, adherence and sustainability of lifestyle change. • Investigates efficacy and effectiveness of healthy lifestyle changes independent of weight change. Healthy lifestyle and optimal weight management appears equally effective in PCOS as in the general population and is the joint responsibility of all health professionals, partnering with women with PCOS. Where complex issues arise, referral to suitably trained allied health professionals needs to be considered. • Low GI/GL diets may provide benefits in reducing weight and IR in women with PCOS. Further research needs to assess additional risk factors including reproductive function and CVD risk. • Identify and define the optimal diet for PCOS management by comparing a range of different dietary approaches (e.g. DASH, Mediterranean or low GI/GL). Health professionals should encourage and advise the following for prevention of weight gain and maintenance of health: • in adults from 18 – 64 years, a minimum of 150 min/week of moderate intensity physical activity or 75 min/week of vigorous intensities or an equivalent combination of both, including muscle strengthening activities on 2 non-consecutive days/week; • in adolescents, at least 60 minutes of moderate to vigorous intensity physical activity/day, including those that strengthen muscle and bone at least 3 times weekly; • activity be performed in at least 10-minute bouts or around 1000 steps, aiming to achieve at least 30 minutes daily on most days. While evidence supports the provision of supervised vigorous aerobic exercise, which may provide greater benefits on PCOS symptoms than other types of exercise (e.g. resistance training), additional larger and longer-term studies are required to: • Characterise optimal exercise prescription for PCOS management. • Identify factors that improve adherence to exercise interventions. • Identify subgroups who respond to exercise with clinical improvements. Health professionals should encourage and advise the following for modest weight-loss, prevention of weight-regain and greater health benefits: • a minimum of 250 min/week of moderate intensity activities or 150 min/week of vigorous intensity or an equivalent combination of both, and muscle strengthening activities involving major muscle groups on 2 non-consecutive days/week; • minimised sedentary, screen or sitting time. Physical activity includes leisure time physical activity, transportation such as walking or cycling, occupational work, household chores, games, sports or planned exercise, in the context of daily, family and community activities. Daily, 10000 steps is ideal, including activities of daily living and 30 minutes of structured physical activity or around 3000 steps. Structuring of recommended activities need to consider women’s and family routines as well as cultural preferences. • To identify behavioural and cognitive strategies that should be targeted in women with PCOS, more observational research that characterises women’s use of self-management strategies is needed. • To aid replication and interpretation of findings, RCTs must clearly define the theoretical frameworks and behavioural components used in intervention design. Assessment and treatment of infertility (as it relates to alcohol and smoking use) Cardiovascular disease risk (as it relates to alcohol and smoking use) • Determine whether women with PCOS are at a higher risk of alcohol and smoking-related infertility complications (with a focus on anovulatory infertility) when compared to women without PCOS. • Determine whether women with PCOS are at a higher risk of smoking-related CVD complications when compared to women without PCOS. Depression and anxiety symptoms, screening and treatment Psychosexual function Body image Eating disorders and disordered eating • To determine accurate prevalence of psychological conditions in PCOS, more adequately powdered cross-sectional studies using structured diagnostic interviews administered by appropriately qualified professionals are required. • Future research should consider the efficacy of different types of psychological interventions in PCOS, with a focus on how changes to mental health symptoms influence engagement with lifestyle change. In particular, the development of a PCOS specific CBT program, tailored to meet the specific mental health needs of women with PCOS is warrant. • To determine accurate prevalence of subclinical sleep disturbances in PCOS, more adequately powdered cross-sectional studies using validated subjective and objective sleep measures are required. • While emerging evidence suggests that disturbed sleep may exacerbate IR via decreasing energy expenditure and increasing adipose tissue deposition, more research in women with PCOS is needed to confirm this hypothesis. • Investigate effects of CBT interventions in women with PCOS who have disturbed sleep (outcomes of interest include food intake, metabolic rate, appetite hormones, weight, adherence to lifestyle changes and PCOS features). • To reduce heterogeneity across studies investigating supplements or herbal medicine, RCTs should focus on specific populations within PCOS (i.e. age, BMI or phenotype) and adopt more consistent approaches to formulation (i.e. limit co-supplementation), dosage, intervention duration and the type of comparator used. • Mechanistic studies are needed to investigate herb- or nutrient-drug interactions (with common pharmacological treatments used in PCOS) and other possible interactions with the biological processes underpinning PCOS. • Research that characterises the uptake of TCIM approaches by women with PCOS, including where they are sourcing information on this topic, will aid health professionals understanding of how to safely navigate the use of adjunct therapies in PCOS management. Abbreviations : BMI Body mass index, CBT Cognitive behavioural therapy, CVD Cardiovascular disease, DASH Dietary approaches to stop hypertension, GI Glycaemic index, GL Glycaemic load, IR Insulin resistance, NAC N-acetyl-cysteine, PCOS Polycystic ovary syndrome, RCT Randomised controlled trial, QoL Quality of life a Recommendations are taken directly from the 2018 International Evidence-Based Guideline for the Assessment and Management of PCOS [ 18 ]. Does not include all recommendations, only those relevant to the findings of this review are presented b EBR Evidence based recommendations: Evidence sufficient to inform a recommendation made by the guideline development group. CCR Clinical Consensus Recommendations: In the absence of evidence, a clinical consensus recommendation has been made by the guideline development group. CPP Clinical Practice Points: Evidence not sought. A practice point has been made by the guideline development group where important issues arose from discussion of evidence-based or clinical consensus recommendations With regards to traditional lifestyle treatment, the majority of studies focussed on weight loss as a primary treatment goal. This indicates more research is warranted to understand the role of diet and exercise in lean women and/or in weight gain prevention. RCTs using lifestyle interventions under isocaloric conditions that investigate effects on IR, body composition and androgens independent of weight loss are needed. Given the high risk of failure with long-term weight management [ 9 , 37 , 40 , 261 ] and high attrition in weight loss trials in PCOS [ 13 ], exploring interventions that focus on weight neural messaging around dietary quality and physical activity may also aid in optimising engagement, adherence and sustainability of lifestyle interventions. Future research should also identify subgroups who respond more favourably to weight loss [ 45 , 53 ], to aid provision of a more targeted and personalised treatment approach. With regards to diet strategies, there is a need for more research understanding the impact of low GI/GL diets on androgen status, as well as the biological mechanisms by which low GI/GL diets may impact reproductive and cardiometabolic outcomes associated with PCOS. With regards to physical activity, additional longer-term studies are required to guide exercise prescription in PCOS, although promising evidence supports the provision of vigorous aerobic exercise performed under supervised conditions (i.e. through referral to an exercise physiologist). While behavioural interventions are essential for long term sustainability of dietary and physical activity change, research in PCOS is scarce and interventions are not well defined. Future research should incorporate appropriate theoretical frameworks and clearly outline behavioural components utilised. This will aid intervention duplication and tailoring of active elements to ensure relevance in women with PCOS. There is currently a lack of research investigating whether women with PCOS are at a higher risk of alcohol and smoking-related complications. This is particularly relevant given the well-established relationship between higher alcohol and cigarette use and rates of depression and anxiety in the general population [ 262 – 265 ]. There is also a need to better understand the relationship between alcohol intake and reproductive outcomes (particularly anovulatory infertility) [ 139 ], as safe alcohol limits in PCOS is currently unknown [ 139 ]. With regards to psychological interventions, the current evidence base for prevalence of mental health concerns in PCOS relies heavily on symptom prevalence. More adequately powered, gold standard prevalence studies using structured diagnostic interviews administered by appropriately qualified professionals are needed. While QoL has recently been highlighted as a core outcome in PCOS research [ 266 ], the application of QoL tools in clinical care is still unclear, with research yet to validate QoL tools longitudinally or identify clinically meaningful differences in QoL scores. The emerging evidence showing support for the use of CBT in PCOS [ 152 – 154 ] highlights an opportunity for tailoring of this psychological intervention to meet the specific mental health needs of women with PCOS, with a focus on how management of mental health symptoms affect lifestyle modifications. CBT that incorporates elements of mindfulness-based stress reduction also warrants further investigation. Future research in PCOS and sleep disorders should include more high-quality research in subclinical disorders using objective sleep measures (polysomnography and actigraphy). Future work should also consider emerging evidence showing that disturbed sleep can detrimentally effect energy expenditure, which may increase adipose tissue deposition and exacerbate IR [ 164 , 184 , 186 , 267 – 271 ], thereby worsening the presentation of PCOS. Further, a consideration of how sleep disturbance can reduce engagement with positive lifestyle changes, for example through the disruption of appetite regulation [ 272 , 273 ] or via contributing to poor mental health outcomes [ 190 , 274 ], is warranted. CBT interventions including elements of stimulus control and psychoeducation are effective non-pharmacological treatments for both clinical sleep disorders and sleep disturbances in the general population [ 275 – 277 ]. RCTs in women with PCOS that investigate effects of CBT on dietary intake, energy metabolism, appetite regulation, anthropometry, adherence to lifestyle changes and PCOS features are required. With regards to TCIM, there is a vast array of literature suggesting some beneficial effects of vitamins (B-group vitamins, folate, vitamins D, E and K), vitamin-like nutrients (bioflavonoids, carnitine and α-LA), minerals (calcium, zinc, selenium, and CrP) and other formulations (such as melatonin, omega-3 fatty acids, probiotics, NAC and cinnamon) in PCOS [ 278 ]. However, the quality of evidence across studies ranges from meta-analyses of RCTs (vitamin D, omega-3 fatty acids and NAC) to single retrospective observational studies (vitamin K and carnitine). In addition, heterogeneity in results related to factors including variable PCOS presentation and study methodology make it difficult to draw definite conclusions. Future research should focus on specific populations within PCOS, for example age, BMI or phenotype (factors which substantially affect nutrient sufficiency), and outline more consistent approaches to supplement formulation, dosage, intervention duration and type of comparator used. Mechanistic studies are also needed to investigate herb- or nutrient-drug interactions (with common pharmacological treatments used in PCOS) and other possible interactions with the biological processes underpinning PCOS. In regards to acupuncture and yoga, more sufficiently powered RCTs are needed to determine clinical relevance and integration into PCOS management is not yet warranted. While current research is not sufficiently robust to support integration of TCIM into routine clinical practice, healthcare providers should broaden their knowledge pertaining to how these therapies can be safely and appropriately utilised as adjuncts to conventional medical management [ 279 – 281 ]. TCIM is frequently used by women, with uptake of TCIM approaches increasing steadily over the past 10 years [ 31 – 35 ]. In women with PCOS, one cross-sectional study ( n =493) found that 70% reported use of TCIM, namely nutritional and herbal supplements [ 282 ]. The most common reasons for use were to treat PCOS symptoms, improve general wellbeing and reduce depression. Of the women using TCIM, 77% had consulted with a complementary practitioner (acupuncturists, chiropractors, naturopaths and massage therapists) [ 282 ]. While the study did not report participants engagement with medical physicians, research in the general population has shown that patients are resistant to discuss TCIM use with their consulting physician [ 283 – 288 ]. Qualified healthcare providers should be involved in TCIM discussions to help ensure appropriate use, maximise possible benefits and minimize potential harm [ 289 ]. For example, to sustain patient engagement in women who express the desire to experiment with supplementation, healthcare providers could consider inositol supplementation, using a nuanced and case-specific approach that encapsulates the variety of pathologies in PCOS. When considering all of the research summarised here, across traditional lifestyle, psychological, sleep and TCIM interventions, there is a clear need for more real-world PCOS research. This involves the translation of findings from clinical trials (where highly selected populations, intensive treatment protocols and expert multidisciplinary teams provide an ideal research setting), into the heterogenous situations that face clinicians [ 290 – 292 ]. Health professionals provide care to women from diverse social contexts, are often restrained by finite resources and are required to juggle many competing demands for their time [ 290 – 292 ]. While some barriers to implementation, including time, resource and access issues are considered in the current PCOS guideline, they were generated by the guideline development groups and research is needed to validate and clarify their proposed concerns. Real-world research is required to: a) fully understand whether lifestyle recommendations can be practically integrated into current healthcare settings; b) tailor interventions to meet the unique needs of women with PCOS; and c) generate evidence on clinical outcomes that are of great relevance to patients and clinicians, such as live birth, miscarriage and menstrual regularity, which can be collected through routine care. It is also important to highlight that while lifestyle management is a first-line treatment for PCOS, the addition of pharmacological therapies to further improve clinical features of hyperandrogenism, menstrual irregularity and infertility are often indicated [ 293 ]. In these instances, prescribing physicians should consider how medical management and lifestyle change can be used in adjunct to optimise treatment. For example, the use of combined oral contraceptive pills may have detrimental effects on weight gain [ 294 ] and mental health [ 295 ], which can be mitigated by appropriate lifestyle intervention. Further, the combination of lifestyle modification and metformin has been shown to lower BMI, subcutaneous adipose tissue and improve menstruation compared with lifestyle modification alone, and hence may have an additive effect on improving cardio-metabolic outcomes in high risk groups [ 296 ].

Using the whole person or holistic definition of health, this review has highlighted emerging areas of research that could be considered for integration into future classifications of lifestyle management in PCOS. When developing lifestyle recommendations for PCOS management, interpreting and communicating evidence not only for diet, physical activity and behavioural interventions, but also psychological, sleep and TCIM approaches, will aid clinicians to deliver patient-centred care by affording women more choice and therefore autonomy over their treatment options. This sentiment aligns with the core objectives underpinning the 2018 PCOS guideline, which sought to understand the unmet needs of women with PCOS through continuing to engage consumers in co-design of guideline development, implementation, translation and dissemination.

The 2018 PCOS guideline includes recommendations on inositol supplementation, though do not include evidence regarding the use of other supplements, herbal medicine or other TCIM approaches, including acupuncture and yoga [ 18 ]. The 2018 guideline highlights that inositol (including myo-inositol (MI) and di-chiro inositol) is a nutritional supplement that may be involved in insulin signalling transduction [ 191 ]. MI in particular is a key endocrine regulator that displays impaired metabolism in PCOS [ 191 ]. MI supplementation has been explored in a meta-analysis of nine RCTs ( n =496), which showed improved metabolic profiles and reduced hyperandrogenism [ 191 ]. These findings are supported by two earlier meta-analyses, reporting improved ovulation, menstrual cyclicity, and hormonal profiles following MI supplementation [ 192 , 193 ]. The 2018 PCOS guideline recommends that inositol (in any form) should be considered as an experimental therapy in PCOS management. The guideline also recognises that women participating in any form of TCIM should be encouraged to advise their health professional. However, it does not consider emerging evidence for the use of other types of TCIM in PCOS treatment as this was outside of the scope of the 2018 guideline. B-group vitamins (B 1 , B 6 and B 12 ), folic acid (B 9 ) and vitamins D, E, and K are critical for several biological processes that can affect metabolic and reproductive features of PCOS. B-group vitamins work alongside folic acid (the synthetic form of folate) to regulate homocysteine (Hcy) via re-methylation of Hcy to methionine [ 194 ]. Hcy is an amino acid that confers an increased risk of CVD at high levels, and which is often deranged in women with PCOS [ 195 ], likely related to a higher prevalence of folate deficiency [ 196 – 198 ]. One RCT explored the use of B-group vitamins combined with folic acid in 60 women with PCOS, and reported a reduction in the Hcy increasing effect of metformin [ 198 ]. Folic acid alone has also been examined in two RCTs of women with PCOS ( n =69 [ 199 ] and n =81 [ 200 ]), improving FINS, HOMA-IR, C-reactive protein, total antioxidant capacity (TAC) and glutathione with doses ≥ 5 mg/day when compared with placebo [ 199 , 200 ]. Regarding vitamin D supplementation, three large-scale meta-analyses reported improvements in measures of IR (HOMA-IR [ 201 , 202 ], FINS [ 201 ]), fasting glucose [ 201 ]), lipid profiles (LDL-C [ 201 – 203 ], TC [ 203 ] and TAG [ 203 ]) and androgens (T) [ 202 ], when compared with placebo. While vitamin E (or tocopherol) has various reported benefits on fertility outcomes in other populations [ 204 ], and has improved androgen profiles when co-supplemented with coenzyme Q10 (CoQ10) in women with PCOS [ 205 ], to date no RCTs have examined the use of vitamin E supplements alone in PCOS. Vitamin K also has limited available literature in PCOS, with only one RCT ( n =84) demonstrating improvements in anthropometry, insulin and androgen profiles following supplementation (90 μg/day Menaquinone-7 for eight weeks), compared with placebo [ 206 ]. Vitamin-like supplements including bioflavonoids, carnitine and alpha-lipoic acid (α-LA) have well-recognised antioxidant properties and play a role in fatty acid and glucose metabolism, providing possible metabolic benefits in PCOS [ 207 ]. Bioflavonoids consist of plant-derived polyphenolic compounds, some of which have been inversely associated with METS in women with PCOS [ 207 ]. In a pilot prospective study of 12 women with PCOS, 36 mg/day of the soy isoflavone genistein for six months improved lipid profiles but not anthropometry, IR, hormonal profiles or menstrual cyclicity [ 208 ]. Carnitine, particularly the active form L-carnitine, is reported to be lower in women with PCOS and linked with hyperandrogenism, hyperinsulinaemia and reduced oocyte quality [ 209 , 210 ]. One RCT explored L-carnitine use in PCOS and found beneficial effects on mental health parameters and markers of oxidative stress [ 211 ], although the integrity of these have come under scrutiny and hence should be interpreted with caution [ 122 212 ]. Regarding α-LA, a small pre-post study ( n =6) administered 1200 mg/day for 16 weeks, and reported improved IR, LDL-C and TAG, though no effects on TAC or plasma oxidation metabolites [ 213 ]. Another RCT reported improved anthropometric (BMI), metabolic (FINS and HDL-C) and reproductive (menstrual cyclicity) features in 46 women with PCOS receiving α-LA supplementation (600 mg/day for 180 days) compared with controls [ 214 ]. However, as these women were co-supplemented with 1000 mg/day D-chiro-inostiol, findings are not isolated to the effects of α-LA alone [ 214 ]. Minerals such as calcium, zinc, selenium, magnesium and chromium picolinate (CrP) have been explored in PCOS due to their reported insulin sensitising, antioxidant and anti-inflammatory properties [ 215 – 217 ]. A small number of studies have also reported women with PCOS are at higher risk of being deficient in calcium [ 218 ], zinc [ 215 , 217 ] and selenium [ 195 ]. A recent systematic review (six RCTs) reported that vitamin D and calcium co-supplementation in women with PCOS improved lipid and androgen profiles, follicular health and menstrual cyclicity [ 219 ]. While these findings are promising, it is difficult to attribute benefits to calcium alone, given calcium is often co-supplemented with vitamin D due to their complementary mechanisms of action. One systematic review (five RCTs) in PCOS reported zinc (often co-supplemented with other nutrients such as calcium, vitamin D and magnesium), improved HOMA-IR, lipids, T, FSH and DHEAS [ 220 ] compared to placebo. Another systematic review (five RCTs) examining selenium supplementation reported reduced IR, oxidative stress and inflammation, while results for anthropometry, lipids, androgens and hirsutism were inconsistent [ 221 ]. Regarding magnesium (an intracellular cation involved in insulin metabolism), while supplementation in PCOS has been associated with reduced IR in observational research [ 222 ], these findings are not supported by data from RCTs, with considerable inconsistencies between studies [ 222 ]. Two meta-analyses examined CrP in women with PCOS [ 223 , 224 ]. While one reported that CrP supplementation reduced BMI, FINS and free testosterone [ 223 ], the other reported decreased IR, but not BMI, and increased levels of T [ 224 ]. Other supplements purported to provide a range of antioxidant and anti-inflammatory benefits, including omega-3 fatty acids, N-acetyl-cysteine (NAC), CoQ10, probiotics, quercetin, resveratrol and melatonin have been explored in PCOS. A meta-analysis (nine RCTs) of women with PCOS ( n =591) receiving omega-3 supplementation reported reductions in HOMA-IR, TC, TAG and LDL-C, though showed no effect on other metabolic parameters or T [ 225 ]. In a meta-analysis of eight RCTs ( n =910) examining NAC supplementation (the acylated form of L-cysteine), researchers reported improved glucose regulation and a greater likelihood of conception and livebirths in women with PCOS compared with placebo [ 226 ]. In a single RCT ( n =60) CoQ10 supplementation (100 mg/day for 12 weeks) improved fasting glucose and insulin, HOMA-IR, insulin sensitivity index and TC, compared with the placebo group [ 227 ]. Two meta-analyses reported probiotics improved FAI, SHBG, IR and blood lipids, with no differences in weight or hirsutism between intervention and placebo groups [ 228 , 229 ]. These findings may be linked to lower microbial diversity and increased intestinal permeability in women with PCOS [ 230 , 231 ]. In regards to quercetin and resveratrol, which are both food derived polyphenols with a strong antioxidant capacity, one systematic review (three experimental studies, n =246 women with PCOS) reported quercetin supplementation improved measures of IR and testosterone levels, but not anthropometry compared with placebo [ 232 ]. Similarly, one RCT in women with PCOS ( n =61) reported resveratrol (800-1500 mg/day for four days) improved androgen and metabolic profiles and oocyte and embryo quality compared with placebo [ 233 ]. Finally, a systematic review (two RCTs and one cell-culture study) investigating the effects of melatonin supplementation in women with PCOS using assisted reproductive technologies reported melatonin significantly increased clinical pregnancy rates but not live birth rates [ 172 ]. A more recent RCT ( n =56) reported improved levels of T, hirsutism, inflammatory and oxidative stress profiles in women receiving 10 g melatonin/day for 12 weeks, compared with placebo [ 234 ]. To date the most recent and comprehensive review (Cochrane review including five RCTs and n =414 women with PCOS) investigating the effects of herbal medicine on reproductive outcomes, reported no difference between the use of Chinese herbal medicine (CHM) and clomiphene for pregnancy rates, and limited evidence of increased pregnancy rate for CHM with clomiphene compared with clomiphene alone [ 235 ]. This review concluded that there was inadequate evidence to promote the use of CHM for the treatment of subfertility in women with PCOS [ 235 ]. Similarly, a smaller systematic review (five studies) investigating the effects of four herbal medicines (green tea, cinnamon, spearmint and black cohosh) on menstrual regularity in PCOS, found limited high-quality evidence from RCTs to support their clinical use and concluded that evidence for safety was lacking [ 236 ]. More recently, a number of small RCTs investigating metabolic and reproductive effects of a range of herbal medicines have been published. Curcumin, an active compound in turmeric ( Curcuma longa), may exert hypoglycemic effects via a number of mechanisms, including attenuation of circulating levels of tumor necrosis factor-α [ 237 ]. One RCT ( n =67) reported decreased levels of fasting glucose following supplementation compared with placebo [ 238 ], while another ( n =51) which used a lower dose (1000 mg/day versus 1500 mg/day) and shorter duration (six weeks versus 12 weeks), reported no between group differences for fasting glucose, HOMA-IR or lipids [ 239 ]. Salvia officinalis or sage contains multiple active compounds that display antioxidant effects and therefore effects on glucose metabolism and insulin sensitivity [ 240 ]. One RCT ( n =72) reported consuming sage extract for eight weeks improved IR and reduced BMI, with no effects on WHR or blood pressure [ 241 ] Foeniculum vulgare or fennel may provide protective effects on hormonal abnormalities in PCOS via its actions as a phytoestrogen [ 242 ]. One RCT ( n =55) reported that six months of fennel tea and dry cupping was as effective as metformin for reducing BMI and menstrual cycle length [ 243 ]. Glycyrrhiza glabra or licorice contains active phytochemicals including isoflavane and glabridin, which have been shown to have antiandrogenic effects [ 244 ]. Two experimental studies in healthy women ( n =9) [ 245 ] and women with PCOS ( n =32) [ 246 ] reported that 3.5 g/day of licorice extract decreased T [ 245 ] and reduced side effects of spironolactone [ 246 ]. Mentha spicata (spearmint), Zingiber offinale Roscoe (ginger), Cinnamomum cassia (cinnamon) and Citrus sinensis (citrus) have been shown to exert anti-inflammatory and hypoglycemic effects [ 247 – 250 ]. One RCT in infertile women with PCOS ( n =60) comparing the effects of a herbal mixture (citrus, ginger, cinnamon and spearmint) with clomiphene citrate (CC), herbal mixture alone, or CC alone reported that the herbal mixture, with or without CC, improved circulating antioxidant levels, IR and fasting blood glucose, but not menstrual regularity when compared to CC alone [ 251 ]. While observations from emerging research are promising, to support the safe translation of findings into the clinical setting there is a clear need for larger clinical trials investigating the efficacy and safety of herbal medicine use in PCOS. Acupuncture may provide beneficial impacts on sympathetic function [ 252 ] and ovarian blood flow [ 253 ] in women with PCOS. A recent meta-analysis of 22 RCTs ( n =2315 women with PCOS) reported recovery of the menstrual period in the acupuncture group when compared with placebo, but no evidence for differences between groups in terms of live birth, pregnancy and ovulation [ 254 ]. While an earlier meta-analysis reported a significant reduction in BMI following acupuncture use, this was mainly due to one RCT ( n =80) which compared acupuncture and the oral contraceptive pill to the oral contraceptive pill alone [ 255 ]. When this study was removed, the pooled analysis was no longer significant [ 255 ]. Yoga gymnastics have been recommended as an example of moderate physical activity in the 2018 evidence-based PCOS guideline [ 18 ]. However, as yoga is considered a mind-body therapy that incorporates aspects of meditation, it may provide additional benefits beyond those gained through other forms of exercise [ 256 ]. While one systematic review (16 observational and experimental studies, n =365 women with PCOS) reported yoga may provide a range of psychological, reproductive and metabolic benefits, no meta-analysis was performed and a limited summary of included studies made it difficult to confirm findings [ 257 ]. A more recent systematic review (11 experimental studies) included a meta-analysis of two RCTs and found that yoga significantly decreased clinical hyperandrogenism, menstrual irregularity and fasting glucose and insulin [ 258 ]. Lastly, findings from a recent RCT ( n =67 women with PCOS) suggests that 90 minutes of yoga per day for six weeks can significantly reduce hirsutism, waist and hip circumference when compared to controls [ 259 ]. Please see Table 5   for a summary of available evidence from meta-analyses and experimental studies investigating the effects of TCIM on PCOS outcomes. Table 5 Reviews and experimental studies investigating the effects of traditional, complimentary and integrative medicine on polycystic ovary syndrome outcomes Intervention N study design N studies; N participants Main findings a References Vitamins  B-group vitamins (B1, B6, and B12) 1 RCT 1; 60 Counteracted Hcy-increasing effect of metformin ↔ HOMA-IR Kilicdag et al. 2005 [ 198 ]  Folate (vitamin B9) 2 RCT 2; 150 ↓ Hcy [ 199 , 200 ], HOMA-β [ 199 ], HOMA-IR [ 200 ], FINS [ 200 ], TC:HDL-C ratio [ 200 ], CRP [ 199 ], MDA [ 199 ] ↑ TAC [ 199 ], GSH [ 199 ] Bahmani et al. 2014 [ 199 ] Asemi et al. 2014 [ 200 ]  Inositols (vitamin B8) 1 SR/MA 9 RCT; 496 ↓ HOMA-IR; ↓ FINS ↔ androstenedione, T, SHBG Unfer et al. 2017 [ 191 ]  Vitamin D 2 SR/MA 23 RCT; 1367 ↓ TC [ 201 ], LDL [ 201 ], TAG [ 201 ], HOMA-IR [ 203 ], FGL [ 203 ], FINS [ 203 ], VLDL-C [ 203 ] ↑ QUICKI [ 203 ] ↔ HDL-C [ 201 ] Guo et al. 2020 [ 201 ] Gao et al. 2021 [ 203 ]  Vitamin E 1 RCT 1; 86 ↓ FGL, HOMA-IR, SHBG, T (only when combined with coenzyme Q10) Izadi et al. 2019 [ 205 ]  Vitamin K 1 RCT 1; 79 ↓ WC, FBM, FINS, HOMA-IR, HOMA-β, TAG, FAI, DHT ↑ skeletal muscle mass, SHBG, QUICKI Tarkesh et al. 2020 [ 206 ] Vitamin-like supplements  Soy isoflavones 1 pilot pre-post prospective 1; 12 ↓TC, LDL-C, LDL-C:HDL-C ratio, TAG Romualdi et al. 2018 [ 208 ]  Carnitine (L-Carnitine) 1 RCT 1; 60 ↓ MDA, MDA:TAC ratio ↑ TAC Jamilian et al. 2017 [ 211 ]  Alpha-lipoic acid 2 pre-post prospective 2; 52 ↓ BMI [ 214 ], IR [ 213 ] , LDL-C [ 213 ], TAG [ 213 ], ovarian cysts [ 214 ] ↑ progesterone [ 214 ] Masharani et al. 2010 [ 213 ] Cianci et al. 2015 [ 214 ] Minerals  Vitamin D and calcium 1 SR/MA 6 RCT; 480 ↓ FINS, HOMA-IR, FGL, T, TAG, VLDL-C, TC, LDL-C, hirsutism ↑ QUICKI, menstrual regularity Shojaeian et al. 2019 [ 219 ]  Zinc 1 SR 5 RCT; 285 ↓ HOMA-IR, HOMA-β, FINS, MDA, CRP, T, FSH, TC, LDL-C, TAG, VLDL-C, DHEAS ↑ TAC, QUICKI Nasiadek et al. 2020 [ 220 ]  Selenium 1 SR 5 RCT; NR ↓ IR, CRP and MDA in some RCTs ↔ (or inconsistent findings) BMI, BW, FGL, blood lipids, androgens, acne, hirsutism Hajizadeh-Sharafabad et al. 2019 [ 221 ]  Magnesium 1 SR 3 RCT; 156 Serum magnesium concentrations were associated with IR but supplementation had inconsistent effects Hamilton et al. 2019 [ 222 ]  Chromium Picolinate 2 SR/MA 11 RCT; 702 ↓ BMI [ 223 ], FINS [ 223 ], IR [ 224 ], T [ 223 ] ↑ T [ 224 ] ↔ BMI [ 224 ], FG [ 223 ] Fazelian et al. [ 223 ] Tang et al. [ 224 ] Other supplements  Omega-3 fatty acids 1 SR/MA 9 RCT; 591 ↓ HOMA-IR, TC, LDL-C and TAG. ↔ FINS, FGL, BMI, androgens Yang et al. 2018 [ 225 ]  N-acetyl-cysteine 1 SR/MA 8 RCTS; 910 ↑ rates of pregnancy and live births Thakker et al. 2015 [ 226 ]  Coenzyme Q10 1 RCT 1; 60 ↓FGL, FINS, HOMA-IR, HOMA-β, , TC, LDL-C ↑ QUICKI Samimi et al. 2017 [ 227 ]  Probiotics 2 SR/MA 19 RCT; 1261 ↓ FINS [ 228 ], TG [ 228 ], VLDL-C [ 228 ], FAI [ 229 ] ↑QUICKI [ 228 ], SHBG [ 229 ] ↔ BW [ 228 ], FGL [ 228 ], HOMA-IR [ 228 ], TC [ 228 ], LDL-C [ 228 ], HDL-C [ 228 ], CRP [ 228 ], DHEA [ 228 ], T [ 229 ] Liao et al. 2018 [ 228 ] Shamasbi et al. 2020 [ 229 ]  Quercetin 1 SR 3 RCT; 246 Some improvement in adiponectin-mediated IR ↔ BW, WHR Pourteymour et al. 2020 [ 232 ]  Resveratrol 1 SR/MA 3 RCT; 131 ↓ T ↑ high-quality oocytes and embryos ↔ BMI, blood lipids, FGL, pregnancy rate Shojaei-Zarghani et al. 2021 [ 233 ]  Melatonin 1 SR/MA 2 RCT and 1 cell culture; 640 ↑ pregnancy rates in assisted reproductive technology Hu et al. 2020 [ 172 ] Herbal medicine  Cinnamon 1 SR/MA 5 RCT; 448 ↓HOMA-IR, TC, LDL, FGL, FINS ↑ HDL ↔ BW Heydarpour et al. 2020 [ 260 ]  Curcumin 2 RCT 2; 118 ↓ FGL [ 238 ], DHEA [ 238 ] ↔ FGL [ 239 ], FINS [ 238 ], blood lipids [ 239 ], IR [ 239 ] Heshmati et al. 2021 [ 238 ] Sohaei et al. 2019 [ 239 ]  Sage 1 RCT 1; 70 ↓ BW, BMI, WC, FGL, FINS, HOMA-IR, QUICKI ↔ WHR Amini et al . 2020 [ 241 ]  Fennel and dry cupping 1 RCT 1; 55 ↓ BMI, cycle length Mokaberinejad et.al. 2019 [ 243 ]  Licorice 1 pre-post prospective 1 quasi-experimental 2; 41 ↓ T [ 245 ] Reduce prevalence of side effects related to the diuretic activity of spironolactone [ 246 ] Armanini et al. 2004 [ 245 ] Armanini et al. 2007 [ 246 ]  Spearmint, ginger, citrus and cinnamon 1 RCT 1; 60 ↓ HOMA-IR, FINS, FGL Ainehchi et al. 2019 [ 251 ]  Chinese herbal medicine 1 SR/MA 4 RCT; 414 ↑ pregnancy rate when taken with clomiphene (versus clomiphene alone) ↔ pregnancy rate when taken alone (versus clomiphene alone) Insufficient evidence for subfertility Zhou et al. 2016 [ 235 ] Other TCIM  Acupuncture 2 SR/MA 31 RCT; 2846 b ↓ BMI [ 255 ], LH [ 254 ], T [ 254 ] ↑ menstrual regularity [ 254 ] ↔ FGL [ 255 ], FINS [ 255 ], live birth [ 254 ], pregnancy rate [ 254 ], ovulation [ 254 ] Wu et al. 2020 [ 254 ] Qu et al. 2016 [ 255 ]  Yoga 2 SR [ 120 , 257 ] 1 SR/MA [ 258 ] 1 RCT [ 259 ] 21; 1059 a ↓ WC [ 259 ], HC [ 259 ], HOMA-IR [ 120 ], FGL [ 258 ], FINS [ 258 ], T [ 120 ], LH [ 120 ], DHEA [ 120 ], androstenedione [ 120 ], adiponectin [ 120 ], clinical hyperandrogenism [ 259 ] ↑ menstrual regularity [ 258 ], menstrual frequency [ 257 ] ↓ stress and anxiety [ 257 ] Shele et al. 2020 [ 120 ] Thakur et al. 2021 [ 257 ] Anita et al. 2021 [ 258 ] Mohseni M et al. 2021 [ 259 ] Abbreviations: ↑ significant increase ( P ≤ 0.05), ↓ significant decrease ( P ≤ 0.05), ↔ no significant change, BMI Body mass index, BW Body weight, DHEAS Dehydroepiandrosterone-sulfate, DHT Dihydrotestosterone, FGL Fasting glucose level, FINS Fasting insulin level, FBM Fat body mass, FSH Follicle stimulating hormone, FT Free testosterone, GSH Glutathione, HC Hip circumference, Hcy Homocysteine, HOMA-IR Homeostatic assessment of insulin resistance, HDL-C High density lipoprotein cholesterol, IR Insulin resistance, QUICKI Quantitative insulin sensitivity check index, QoL Quality of life, MDA Malondialdehyde, MA Meta-analysis, NR Not reported, OCP Oral Contraceptive Pill, RCT Randomised controlled trial, SHBG Sex hormone binding globulin, SR Systematic review, T Testosterone, TAC Total antioxidant capacity, TC Total cholesterol, TAG Triglycerides, TCIM Traditional, complimentary and integrative medicine, VLDL-C Very low density lipoprotein cholesterol, WC Waist circumference, WHR Wait hip ratio a Summarises commonly used measures in PCOS research and does not report on all measured outcomes. For prospective pre-post studies significant changes from baseline are reported. For RCTs significant changes between intervention(s) and control and reported b Not all participants are included in the findings reported here (e.g. where findings from subgroup analysis are reported) Reviews and experimental studies investigating the effects of traditional, complimentary and integrative medicine on polycystic ovary syndrome outcomes Counteracted Hcy-increasing effect of metformin ↔ HOMA-IR ↓ Hcy [ 199 , 200 ], HOMA-β [ 199 ], HOMA-IR [ 200 ], FINS [ 200 ], TC:HDL-C ratio [ 200 ], CRP [ 199 ], MDA [ 199 ] ↑ TAC [ 199 ], GSH [ 199 ] Bahmani et al. 2014 [ 199 ] Asemi et al. 2014 [ 200 ] ↓ HOMA-IR; ↓ FINS ↔ androstenedione, T, SHBG ↓ TC [ 201 ], LDL [ 201 ], TAG [ 201 ], HOMA-IR [ 203 ], FGL [ 203 ], FINS [ 203 ], VLDL-C [ 203 ] ↑ QUICKI [ 203 ] ↔ HDL-C [ 201 ] Guo et al. 2020 [ 201 ] Gao et al. 2021 [ 203 ] ↓ WC, FBM, FINS, HOMA-IR, HOMA-β, TAG, FAI, DHT ↑ skeletal muscle mass, SHBG, QUICKI ↓ MDA, MDA:TAC ratio ↑ TAC ↓ BMI [ 214 ], IR [ 213 ] , LDL-C [ 213 ], TAG [ 213 ], ovarian cysts [ 214 ] ↑ progesterone [ 214 ] Masharani et al. 2010 [ 213 ] Cianci et al. 2015 [ 214 ] ↓ FINS, HOMA-IR, FGL, T, TAG, VLDL-C, TC, LDL-C, hirsutism ↑ QUICKI, menstrual regularity ↓ HOMA-IR, HOMA-β, FINS, MDA, CRP, T, FSH, TC, LDL-C, TAG, VLDL-C, DHEAS ↑ TAC, QUICKI ↓ IR, CRP and MDA in some RCTs ↔ (or inconsistent findings) BMI, BW, FGL, blood lipids, androgens, acne, hirsutism ↓ BMI [ 223 ], FINS [ 223 ], IR [ 224 ], T [ 223 ] ↑ T [ 224 ] ↔ BMI [ 224 ], FG [ 223 ] Fazelian et al. [ 223 ] Tang et al. [ 224 ] ↓ HOMA-IR, TC, LDL-C and TAG. ↔ FINS, FGL, BMI, androgens ↓FGL, FINS, HOMA-IR, HOMA-β, , TC, LDL-C ↑ QUICKI ↓ FINS [ 228 ], TG [ 228 ], VLDL-C [ 228 ], FAI [ 229 ] ↑QUICKI [ 228 ], SHBG [ 229 ] ↔ BW [ 228 ], FGL [ 228 ], HOMA-IR [ 228 ], TC [ 228 ], LDL-C [ 228 ], HDL-C [ 228 ], CRP [ 228 ], DHEA [ 228 ], T [ 229 ] Liao et al. 2018 [ 228 ] Shamasbi et al. 2020 [ 229 ] Some improvement in adiponectin-mediated IR ↔ BW, WHR ↓ T ↑ high-quality oocytes and embryos ↔ BMI, blood lipids, FGL, pregnancy rate ↓HOMA-IR, TC, LDL, FGL, FINS ↑ HDL ↔ BW ↓ FGL [ 238 ], DHEA [ 238 ] ↔ FGL [ 239 ], FINS [ 238 ], blood lipids [ 239 ], IR [ 239 ] Heshmati et al. 2021 [ 238 ] Sohaei et al. 2019 [ 239 ] ↓ BW, BMI, WC, FGL, FINS, HOMA-IR, QUICKI ↔ WHR 1 pre-post prospective 1 quasi-experimental ↓ T [ 245 ] Reduce prevalence of side effects related to the diuretic activity of spironolactone [ 246 ] Armanini et al. 2004 [ 245 ] Armanini et al. 2007 [ 246 ] ↑ pregnancy rate when taken with clomiphene (versus clomiphene alone) ↔ pregnancy rate when taken alone (versus clomiphene alone) Insufficient evidence for subfertility ↓ BMI [ 255 ], LH [ 254 ], T [ 254 ] ↑ menstrual regularity [ 254 ] ↔ FGL [ 255 ], FINS [ 255 ], live birth [ 254 ], pregnancy rate [ 254 ], ovulation [ 254 ] Wu et al. 2020 [ 254 ] Qu et al. 2016 [ 255 ] 2 SR [ 120 , 257 ] 1 SR/MA [ 258 ] 1 RCT [ 259 ] ↓ WC [ 259 ], HC [ 259 ], HOMA-IR [ 120 ], FGL [ 258 ], FINS [ 258 ], T [ 120 ], LH [ 120 ], DHEA [ 120 ], androstenedione [ 120 ], adiponectin [ 120 ], clinical hyperandrogenism [ 259 ] ↑ menstrual regularity [ 258 ], menstrual frequency [ 257 ] ↓ stress and anxiety [ 257 ] Shele et al. 2020 [ 120 ] Thakur et al. 2021 [ 257 ] Anita et al. 2021 [ 258 ] Mohseni M et al. 2021 [ 259 ] Abbreviations: ↑ significant increase ( P ≤ 0.05), ↓ significant decrease ( P ≤ 0.05), ↔ no significant change, BMI Body mass index, BW Body weight, DHEAS Dehydroepiandrosterone-sulfate, DHT Dihydrotestosterone, FGL Fasting glucose level, FINS Fasting insulin level, FBM Fat body mass, FSH Follicle stimulating hormone, FT Free testosterone, GSH Glutathione, HC Hip circumference, Hcy Homocysteine, HOMA-IR Homeostatic assessment of insulin resistance, HDL-C High density lipoprotein cholesterol, IR Insulin resistance, QUICKI Quantitative insulin sensitivity check index, QoL Quality of life, MDA Malondialdehyde, MA Meta-analysis, NR Not reported, OCP Oral Contraceptive Pill, RCT Randomised controlled trial, SHBG Sex hormone binding globulin, SR Systematic review, T Testosterone, TAC Total antioxidant capacity, TC Total cholesterol, TAG Triglycerides, TCIM Traditional, complimentary and integrative medicine, VLDL-C Very low density lipoprotein cholesterol, WC Waist circumference, WHR Wait hip ratio a Summarises commonly used measures in PCOS research and does not report on all measured outcomes. For prospective pre-post studies significant changes from baseline are reported. For RCTs significant changes between intervention(s) and control and reported b Not all participants are included in the findings reported here (e.g. where findings from subgroup analysis are reported)

Polycystic ovary syndrome (PCOS) is a common condition affecting up to 13% of reproductive-aged women [ 1 ]. It is diagnosed through the European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine (ESRHE/ASRM) criteria, requiring two of the following features: polycystic ovaries on ultrasound, oligoovulatory or anovulatory cycles and biochemical or clinical hyperandrogenism [ 2 ]. Women with PCOS experience a combination of reproductive (infertility, pregnancy complications) [ 3 ], metabolic (risk factors for and conditions of type 2 diabetes (T2DM) and cardiovascular disease (CVD)) [ 4 , 5 ] and psychological (conditions including anxiety, depression, poor quality of life (QoL), disordered eating) comorbidities [ 6 , 7 ]. Insulin resistance (IR) is defined as a key pathophysiological feature in PCOS, contributing to hyperandrogenism and worsening the clinical presentation of PCOS. While lean women present with IR in a form that is mechanistically different from IR caused by excess weight, overweight and obesity further exacerbate IR and consequent hyperinsulinaemia [ 8 ]. Women with PCOS also display a higher rate of weight gain over time [ 9 ] and a greater prevalence of overweight and obesity [ 10 ], which can further contribute to this worsening of IR and hence worsening of the presentation of PCOS [ 11 ]. The reason for this is unclear, but may be related to differences in intrinsic psychological and biological mechanisms [ 12 – 15 ], or extrinsic lifestyle factors such as diet and physical activity [ 16 , 17 ]. Improving IR and excess adiposity are therefore key targets in PCOS management. The International Evidence-Based Guideline for the Assessment and Management of PCOS [ 18 ], highlights lifestyle intervention as the primary early management strategy. Lifestyle interventions are traditionally defined as those designed to improve dietary intake or physical activity through appropriate behavioural support. In the 2018 PCOS guideline, lifestyle management is recommended for general health benefits [ 18 ]. Given that excess weight is associated with increased IR in PCOS [ 8 ], the guideline additionally promotes weight management, defined as: 1) weight gain prevention in all women with PCOS, and 2) achieving and maintaining modest weight loss in women with excess weight [ 18 ]. Lifestyle interventions in PCOS management can also be viewed as a broader construct beyond physical health. Since the emergence of the biopsychosocial model of healthcare in 1977, health disciplines have seen a gradual shift away from the classical biomedical model (where health is defined as the ‘absence of disease’) towards whole person or holistic care [ 19 ]. This is an approach that reflects many facets of the patient context, via integrating care that addresses biological, psychological, social, spiritual and ecological aspects [ 20 ]. It therefore requires a range of different treatment strategies to improve health. Provision of whole person or holistic care has been identified as a core objective of healthcare reforms internationally [ 21 – 23 ]. In line with these reforms the PCOS guideline recognises the importance of emotional wellbeing to overall health and QoL in women living with PCOS [ 18 ]. It also highlights evidence which suggests that the psychological impact associated with PCOS is under-appreciated in clinical care [ 4 , 5 ], and that few women are satisfied with the mental health support they receive [ 6 , 7 ]. Recommendations for appropriate screening, assessment and treatment strategies for anxiety, depression, psychosexual dysfunction, eating disorders and poor body image are provided [ 18 ]. These specific areas of emotional wellbeing are of particular concern, with research showing a higher prevalence and severity of depression and anxiety [ 24 , 25 ], lower scores for satisfaction with sex life and feeling sexually attractive [ 26 ] and a higher prevalence of disordered eating and eating disorders [ 7 ] in women with PCOS. Features of PCOS, in particular hirsutism and increased weight, have also been shown to negatively affect body image [ 27 , 28 ], with poor body image being strongly related to depression in women with PCOS [ 29 , 30 ]. While the current PCOS guideline is comprehensive, considering all available evidence at the time of development and providing best-practice recommendations for necessary screening, risk assessment and management, it could not possibly cover all aspects of PCOS care. An International Delphi process was used to prioritise clinical questions, with consensus reached through extensive consultation with both consumers and multidisciplinary clinicians with expertise in PCOS care. Therapies, such as traditional, complementary and integrative medicine (TCIM), supplement use, sleep and meditation interventions are either briefly considered or not at all included in the 2018 PCOS guideline. Many of these therapies are novel and there is a paucity of evidence to support intervention efficacy on PCOS outcomes. However, as patient interest in these types of non-pharmacological interventions are growing [ 31 – 35 ], it is prudent to provide more guidance to healthcare providers in this area on their potential efficacy in PCOS. Whole person or holistic care recognises that the doctor-patient relationship should be one of open dialogue, where healthcare providers involve the patient in negotiating their care and recognises patient’s autonomy to guide treatment (Figure 1 ) [ 36 ]. Fig. 1 Viewing lifestyle modifications through a whole person or holistic care lens. The key features of whole person or holistic care listed in the centre of the figure have been adapted from Thomas et al. [ 20 ]. ‘Recognises individual personhood’ relates to focusing on the unique needs of the person rather than the disease. ‘Importance of therapeutic relationship’ emphasises patient autonomy and responsibility. ‘Acknowledges humanity of the doctor’ considers the doctors’ ability to self-reflect on how they engage in the care of the patient. ‘Health as more than absence of disease’ incorporates the mental, emotional, physical, environmental and social needs of the patient. ‘Employs a range of treatment modalities’ promotes continuity of care across health disciplines, and while it may include traditional, complementary and integrative medicine (TCIM), TCIM is not holistic if used in isolation and without adequate integration into conventional healthcare Viewing lifestyle modifications through a whole person or holistic care lens. The key features of whole person or holistic care listed in the centre of the figure have been adapted from Thomas et al. [ 20 ]. ‘Recognises individual personhood’ relates to focusing on the unique needs of the person rather than the disease. ‘Importance of therapeutic relationship’ emphasises patient autonomy and responsibility. ‘Acknowledges humanity of the doctor’ considers the doctors’ ability to self-reflect on how they engage in the care of the patient. ‘Health as more than absence of disease’ incorporates the mental, emotional, physical, environmental and social needs of the patient. ‘Employs a range of treatment modalities’ promotes continuity of care across health disciplines, and while it may include traditional, complementary and integrative medicine (TCIM), TCIM is not holistic if used in isolation and without adequate integration into conventional healthcare This review provides an extensive overview of evidence to date on lifestyle strategies used to optimise management of PCOS. Using a holistic definition of patient care, this review considers the traditional components of lifestyle change (diet, physical activity and behavioural change), psychological and sleep interventions, as well as TCIM approaches (supplements, herbal medicine, acupuncture and yoga). To improve translation of findings, evidence summaries are accompanied by an overview of relevant recommendations from the existing PCOS guideline. This highlights where emerging evidence supports current recommendations or provides new insights for research. As this is a narrative review, while evidence summaries include peer-reviewed journal articles identified from databases including Medline OVID, this is supplemented by expert opinion of the authors.

The current guideline highlights the need for awareness, and appropriate assessment (such as stepwise screening) and management, of QoL, depression and anxiety, psychosexual dysfunction, negative body image and disordered eating [ 18 ]. The guideline emphasises the importance of clinicians and women working in partnership to address women’s individual priorities; understanding that the impact of PCOS on an individual’s QoL is key to delivering meaningful outcomes [ 147 , 148 ]. To assist women to communicate with clinicians about what is important to them, the PCOS Question Prompt List [ 149 ] was developed and is consistent with the 2018 guideline. The 2018 guideline recommends screening for risk factors and symptoms of depression and anxiety at time of diagnosis. Women with positive screening results should be supported with further assessment and treatment by appropriately qualified clinicians. To screen for psychosexual dysfunction tools such as the Female Sexual Function Index [ 150 ] should be utilised. If negative body image, disordered eating or eating disorders are suspected, the PCOS guideline outlines a stepped approach for screening, and where appropriate promotes the use of psychological therapy offered by trained health professionals, which should be guided by regional clinical practice guidelines [ 18 ]. While the PCOS guideline provides justification and summarises evidence for mental health screening and diagnostic assessment, there is also a need for consideration of additional aspects, such as the efficacy of different types of psychological interventions and how psychological interventions influence engagement with lifestyle change. This is important, as poorer mental health outcomes at baseline are positively associated with higher rates of attrition in lifestyle interventions [ 13 ]. Cognitive behavioural interventions could be considered to improve engagement and adherence to healthy lifestyle in women with PCOS. Research has shown support for a range of different psychological interventions, such as counselling [ 151 ], cognitive behavioural therapy (CBT) [ 152 – 154 ] and mindfulness meditation [ 155 , 156 ], helping to change the way clinicians’ approach and deliver optimal PCOS management. CBT is one of the most widely-researched psychological interventions, and is well-recognised as the most effective psychological treatment for depression and anxiety [ 157 ]. One RCT showed that eight weekly group CBT sessions were effective in improving QoL ratings and reducing psychological fatigue in women with PCOS [ 152 ]. Another more recent RCT investigated the outcome of a 1 year three-component intervention focusing on CBT, diet and exercise [ 154 ] and reported improvements in self-esteem and depressive symptoms as compared to usual care [ 154 ]. Similarly, an RCT by Cooney et al. [ 153 ], comparing the effects of CBT and lifestyle modification versus lifestyle modification alone, reported the CBT/lifestyle modification group lost more than twice as much weight per week and had greater improvements in QoL compared to lifestyle only. Depression scores decreased in the overall group and there was no difference between the two groups [ 153 ]. Lastly, a pilot intervention study of adolescents with PCOS has shown promising results for the use of CBT in the reduction of weight and improvement in depressive symptoms [ 158 ]. Mindfulness meditation programs have gained increasing popularity over the past few decades, and are being included as part of clinical trials to reduce stress and improve psychological wellbeing across a range of medical conditions [ 159 ]. Mindfulness meditation can be used to reduce the production of adrenal androgens, activated via the adrenal glands as a direct result of psychological distress [ 156 ]. Despite the proposed benefits, there are very few studies investigating the use of mindfulness meditation as a treatment for psychological symptoms associated with PCOS. One RCT ( n =86) compared the provision of an eight week mindfulness-based stress reduction (MBSR) program, and found that when compared to the control group (health education), the MBSR group produced greater reductions in perceived stress, depressive symptoms and fasting blood glucose [ 160 ]. Similarly, another RCT investigating the impact of mindfulness meditation for eight weeks in PCOS showed reduced stress, depression and anxiety symptoms, and increased life satisfaction and QoL in the intervention group compared to no treatment [ 156 ]. In adolescents with PCOS ( n =37), a pilot RCT reported higher levels of nutrition and physical activity self-efficacy following a mindfulness and self-management program [ 161 ]. Mindfulness-based cognitive therapy (MBCT) combines both elements of MBSR and CBT, but as yet there are no trials investigating this intervention in PCOS. In addition to CBT and mindfulness meditation, there is some evidence to support group counselling sessions as beneficial in conjunction with exercise programs to increase and support weight loss [ 151 ]. In one RCT ( n =17) participants followed a high-intensity aerobic exercise program for eight weeks, followed by eight weeks of group counselling [ 151 ]. Qualitative analysis of data taken from the group counselling and physical exercise sessions revealed that development of supportive relationships was important for successful behavioural change. By fostering the exchange of narratives relating to their illness (e.g. effects of PCOS on aspects of everyday life), and generating feedback between group members, counselling sessions helped to reduce social isolation and improve adherence to the exercise intervention [ 151 ]. Please see Table 3 for a summary of experimental studies investigating effects of psychological interventions on PCOS outcomes. Table 3 Experimental studies investigating the effects of psychological interventions on polycystic ovary syndrome outcomes References Study design; study length; N participants Intervention Main findings Abdollahi et al. 2019 [ 152 ] Parallel RCT; 8 wk; 74 I = 8 weekly CBT C = minimal intervention ↑ QoL (PCOSQ) for I compared with C ↓ psychological fatigue (FIS) for I compared with C Jiskoot et al. 2020 [ 162 ] Jiskoot et al. 2020 [ 154 ] Parallel RCT; 1 yr; 183 I = 20 group sessions of CBT combined with nutrition advice and exercise C = usual care ↓ depression (BDI-II) and BW in I compared with C ↑ self-esteem (RSES) in I compared with C Oberg et al. 2020 [ 132 ] Parallel RCT; 16 wk with a follow-up at 1 yr; 68 I = behavioural modification program C = minimal intervention ↓ anxiety (PGWBI) and depressed mood (PGWBI) in I compared with C ↑ higher general health (PGWBI) in I compared with C Cooney et al. 2018 [ 153 ] Parallel RCT; 16 wk; 31 I = 8 weekly CBT with lifestyle modification C = no psychological intervention with lifestyle modification ↓ BW in I compared with control ↑ QoL (PCOSQ) in I compared with control Raja-Khan et al. 2017 [ 160 ] Parallel RCT; 16 wk; 86 I = 8 weekly MBSR C = 8 weekly health education sessions (diet and exercise education) ↑ mindfulness (TMS) in I compared with C ↓ perceived stress (PSS-10) in I compared with C Stefanaki et al. 2015 [ 156 ] Parallel RCT; 8 wk; 38 I = MBSR C = minimal intervention ↓ depression (DASS21), stress (DASS21) and cortisol in I compared with control Roessler et al. 2012 [ 151 ] a Roessler et al. 2013 [ 163 ] b Cross-over randomised; 8 wk per arm and 16 wk total; 17 8 wk high-intensity aerobic exercise (including a ramp-up period of two weeks) and 8 wk group counselling in a cross-over design without a wash-out period Relationships between the participants were important for changes in behaviour, especially relationships which generated helpful peer feedback and reduced social isolation ↓ BW and BMI after 16 wk only in the group who started with group counselling Rofey et al. 2009 [ 158 ] Single arm experimental; 8 wk; 12 8 one-on-one CBT, 3 family-based CBT and lifestyle goals (diet and exercise) ↓ BW, BMI and depression (CDI) ↑ health-related QoL (IWQoL-K) Abbreviations : ↑ significant increase ( P ≤ 0.05), ↓ significant decrease ( P ≤ 0.05), BDI-II Beck Depression Inventory-II, BP Blood pressure, BMI Body mass index, BW Body weight, CDI Children’s Depression Inventory, C Control, CBT Cognitive behavioural therapy, CES-D Centre for Epidemiologic Studies – Depression Scale, DASS21 Depression Anxiety Stress Scales-21, DSM-IV Diagnostic and Statistical Manual of Mental Disorders (fourth edition), FGL Fasting glucose level, FIS Fatigue Impact Scale, I Intervention, IWQoL-K Impact of Weight on Quality of Life Questionnaire—Kids, HP Hip circumference, MBSR Mindfulness-based stress reduction, PSS-10 Perceived Stress Scale-10, PCOS Polycystic ovary syndrome, PCOSQ Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire, PGWBI Psychological Well-Being Index, QoL Quality of life, RSES Rosenberg Self Esteem Scale, RCT Randomized controlled trial, STAI State-Trait Anxiety Inventory, SSP Swedish Universities Scale of Personalities, TMS Toronto Mindfulness Scale, TSST Trier Social Stress Test, WC Waist circumference a Qualitative analysis only b Statistical analysis compares order of intervention arms (e.g. counselling followed by exercise versus exercise followed by counselling) and doesn’t compare effects of counselling versus exercise Experimental studies investigating the effects of psychological interventions on polycystic ovary syndrome outcomes I = 8 weekly CBT C = minimal intervention ↑ QoL (PCOSQ) for I compared with C ↓ psychological fatigue (FIS) for I compared with C Jiskoot et al. 2020 [ 162 ] Jiskoot et al. 2020 [ 154 ] I = 20 group sessions of CBT combined with nutrition advice and exercise C = usual care ↓ depression (BDI-II) and BW in I compared with C ↑ self-esteem (RSES) in I compared with C I = behavioural modification program C = minimal intervention ↓ anxiety (PGWBI) and depressed mood (PGWBI) in I compared with C ↑ higher general health (PGWBI) in I compared with C I = 8 weekly CBT with lifestyle modification C = no psychological intervention with lifestyle modification ↓ BW in I compared with control ↑ QoL (PCOSQ) in I compared with control I = 8 weekly MBSR C = 8 weekly health education sessions (diet and exercise education) ↑ mindfulness (TMS) in I compared with C ↓ perceived stress (PSS-10) in I compared with C I = MBSR C = minimal intervention Roessler et al. 2012 [ 151 ] a Roessler et al. 2013 [ 163 ] b 8 wk high-intensity aerobic exercise (including a ramp-up period of two weeks) and 8 wk group counselling in a cross-over design without a wash-out period Relationships between the participants were important for changes in behaviour, especially relationships which generated helpful peer feedback and reduced social isolation ↓ BW and BMI after 16 wk only in the group who started with group counselling 8 one-on-one CBT, 3 family-based CBT and lifestyle goals (diet and exercise) ↓ BW, BMI and depression (CDI) ↑ health-related QoL (IWQoL-K) Abbreviations : ↑ significant increase ( P ≤ 0.05), ↓ significant decrease ( P ≤ 0.05), BDI-II Beck Depression Inventory-II, BP Blood pressure, BMI Body mass index, BW Body weight, CDI Children’s Depression Inventory, C Control, CBT Cognitive behavioural therapy, CES-D Centre for Epidemiologic Studies – Depression Scale, DASS21 Depression Anxiety Stress Scales-21, DSM-IV Diagnostic and Statistical Manual of Mental Disorders (fourth edition), FGL Fasting glucose level, FIS Fatigue Impact Scale, I Intervention, IWQoL-K Impact of Weight on Quality of Life Questionnaire—Kids, HP Hip circumference, MBSR Mindfulness-based stress reduction, PSS-10 Perceived Stress Scale-10, PCOS Polycystic ovary syndrome, PCOSQ Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire, PGWBI Psychological Well-Being Index, QoL Quality of life, RSES Rosenberg Self Esteem Scale, RCT Randomized controlled trial, STAI State-Trait Anxiety Inventory, SSP Swedish Universities Scale of Personalities, TMS Toronto Mindfulness Scale, TSST Trier Social Stress Test, WC Waist circumference a Qualitative analysis only b Statistical analysis compares order of intervention arms (e.g. counselling followed by exercise versus exercise followed by counselling) and doesn’t compare effects of counselling versus exercise